Geode Capital Management’s Enliven Therapeutics ELVN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.7M | Buy |
882,753
+63,580
| +8% | +$1.28M | ﹤0.01% | 2017 |
|
|
2025
Q1 | $16.1M | Buy |
819,173
+56,455
| +7% | +$1.11M | ﹤0.01% | 2016 |
|
|
2024
Q4 | $17.2M | Buy |
762,718
+12,510
| +2% | +$282K | ﹤0.01% | 2051 |
|
|
2024
Q3 | $19.2M | Buy |
750,208
+67,813
| +10% | +$1.73M | ﹤0.01% | 2000 |
|
|
2024
Q2 | $15.9M | Buy |
682,395
+206,939
| +44% | +$4.84M | ﹤0.01% | 2051 |
|
|
2024
Q1 | $8.36M | Buy |
475,456
+10,799
| +2% | +$190K | ﹤0.01% | 2431 |
|
|
2023
Q4 | $6.43M | Buy |
464,657
+31,685
| +7% | +$439K | ﹤0.01% | 2575 |
|
|
2023
Q3 | $5.92M | Buy |
432,972
+18,528
| +4% | +$253K | ﹤0.01% | 2560 |
|
|
2023
Q2 | $8.46M | Buy |
414,444
+379,056
| +1,071% | +$7.74M | ﹤0.01% | 2384 |
|
|
2023
Q1 | $775K | Sell |
35,388
-102,338
| -74% | -$2.24M | ﹤0.01% | 3463 |
|
|
2022
Q4 | $563K | Buy |
137,726
+32,651
| +31% | +$133K | ﹤0.01% | 3609 |
|
|
2022
Q3 | $239K | Buy |
105,075
+49,336
| +89% | +$112K | ﹤0.01% | 4101 |
|
|
2022
Q2 | $68K | Buy |
55,739
+1,276
| +2% | +$1.56K | ﹤0.01% | 4700 |
|
|
2022
Q1 | $102K | Sell |
54,463
-314
| -0.6% | -$588 | ﹤0.01% | 4655 |
|
|
2021
Q4 | $123K | Hold |
54,777
| – | – | ﹤0.01% | 4657 |
|
|
2021
Q3 | $223K | Buy |
54,777
+3,304
| +6% | +$13.5K | ﹤0.01% | 4403 |
|
|
2021
Q2 | $406K | Sell |
51,473
-53,471
| -51% | -$422K | ﹤0.01% | 4033 |
|
|
2021
Q1 | $885K | Buy |
104,944
+2,643
| +3% | +$22.3K | ﹤0.01% | 3606 |
|
|
2020
Q4 | $2.26M | Buy |
102,301
+19,385
| +23% | +$427K | ﹤0.01% | 3020 |
|
|
2020
Q3 | $1.69M | Buy |
82,916
+570
| +0.7% | +$11.6K | ﹤0.01% | 2960 |
|
|
2020
Q2 | $2.28M | Buy |
+82,346
| New | +$2.28M | ﹤0.01% | 2772 |
|